Rare Thyroid Therapeutics announced today that it has accepted an offer for an acquisition by Swedish late stage development company PledPharma, listed on Nasdaq Stockholm main market. Together the companies will form a new company, focused on late-stage orphan drug development that is planned to be renamed Egetis Therapeutics. The company will have two orphan drugs in late stage development; Emcitate, for the treatment of MCT8 deficiency and Aladote, for the treatment of severe paracetamol intoxication. Following a planned fully guaranteed rights issue, the company will have enough funding to bring both products through regulatory approvals in the EU and US. For more details around the acquisition, please visit the homepage of PledPharma.